The company shared its second quarter financial results along with updates on its operations.
“Our strategy to transform Aziyo into a high growth drug-eluting biomatrix product company continues to move forward,” CEO Randy Mills, PhD, said in a news release. “We are in discussions with several interested parties to divest our orthopedics business.”
Net sales in the second quarter were $10.3 million, down from $12.6 million in the same time last year. The decrease was largely due to a viable bone matrix recall, which led to a reversal of $3 million in second quarter revenue.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
